CD274 and neoplasm: We hypothesized that low-risk patients could derive benefits from immunotherapy because antibodies against immunological escape genes have been shown to enhance the responses of tumor-related T cells to tumor-related antigens, and upregulation of PD-L1 on tumor cells or immune cells has been linked to improved anti-PD1/PD-L1 immunotherapy effectiveness.